Show simple item record

dc.contributor.authorDeshmukh, Shivprasad S.
dc.contributor.authorParadkar, Anant R
dc.contributor.authorAbrahmsén-Alami, S.
dc.contributor.authorGovender, R.
dc.contributor.authorViridén, A.
dc.contributor.authorWinge, F.
dc.contributor.authorMatic, H.
dc.contributor.authorBooth, J.
dc.contributor.authorKelly, Adrian L.
dc.date.accessioned2020-10-26T11:16:08Z
dc.date.accessioned2020-11-05T11:36:50Z
dc.date.available2020-10-26T11:16:08Z
dc.date.available2020-11-05T11:36:50Z
dc.date.issued2020-02
dc.identifier.citationDeshmukh S, Paradkar A, Abrahmsén-Alami S et al (2020) Injection moulded controlled release amorphous solid dispersions: Synchronized drug and polymer release for robust performance. International Journal of Pharmaceutics. 575: 118908.en_US
dc.identifier.urihttp://hdl.handle.net/10454/18155
dc.descriptionYesen_US
dc.description.abstractA study has been carried out to investigate controlled release performance of caplet shaped injection moulded (IM) amorphous solid dispersion (ASD) tablets based on the model drug AZD0837 and polyethylene oxide (PEO). The physical/chemical storage stability and release robustness of the IM tablets were characterized and compared to that of conventional extended release (ER) hydrophilic matrix tablets of the same raw materials and compositions manufactured via direct compression (DC). To gain an improved understanding of the release mechanisms, the dissolution of both the polymer and the drug were studied. Under conditions where the amount of dissolution media was limited, the controlled release ASD IM tablets demonstrated complete and synchronized release of both PEO and AZD0837 whereas the release of AZD0837 was found to be slower and incomplete from conventional direct compressed ER hydrophilic matrix tablets. Results clearly indicated that AZD0837 remained amorphous throughout the dissolution process and was maintained in a supersaturated state and hence kept stable with the aid of the polymeric carrier when released in a synchronized manner. In addition, it was found that the IM tablets were robust to variation in hydrodynamics of the environment and PEO molecular weight.en_US
dc.description.sponsorshipThe research was funded by AstraZeneca, Sweden.en_US
dc.language.isoenen_US
dc.rights© 2019 Elsevier B.V. All rights reserved. Reproduced in accordance with the publisher's self-archiving policy. This manuscript version is made available under the CC-BY-NC-ND 4.0 license.en_US
dc.subjectOral solid dosage (OSD)en_US
dc.subjectPolymer releaseen_US
dc.subjectRelease robustnessen_US
dc.subjectPoorly soluble drugen_US
dc.subjectPolyethylene oxide (PEO)en_US
dc.subjectHot melt extrusion (HME)en_US
dc.subjectInjection moulding (IM)en_US
dc.subjectControlled releaseen_US
dc.subjectAmorphous solid dispersion (ASD)en_US
dc.titleInjection moulded controlled release amorphous solid dispersions: Synchronized drug and polymer release for robust performanceen_US
dc.status.refereedYesen_US
dc.date.application2019-12-03
dc.typeArticleen_US
dc.type.versionAccepted manuscripten_US
dc.identifier.doihttps://doi.org/10.1016/j.ijpharm.2019.118908
dc.date.updated2020-10-26T11:16:15Z
refterms.dateFOA2020-11-05T11:37:27Z
dc.date.accepted2019-11-24


Item file(s)

Thumbnail
Name:
Kelly_et_al_IJP.pdf
Size:
292.1Kb
Format:
PDF
Thumbnail
Name:
Kelly_et_al_IJP_Supporting_inf ...
Size:
177.8Kb
Format:
PDF
Thumbnail
Name:
SupportinginformationforManusc ...
Size:
694.6Kb
Format:
Microsoft Word 2007
Description:
To keep suppressed
Thumbnail
Name:
AZBRADFORDManuscrip_5_Nov_2019.docx
Size:
183.1Kb
Format:
Microsoft Word 2007
Description:
To keep suppressed

This item appears in the following Collection(s)

Show simple item record